November 2012 - Page 8 of 15

ThursdayNov 15, 2012 6:27 pm

GlobalWise Investments, Inc. (GWIV) Reports Strong Financial Results with Double-Digit Growth

GlobalWise Investments and its wholly owned subsidiary Intellinetics, an enterprise content management (“ECM”) software development, sales, and marketing company, just announced financial results for the third quarter and nine months ended September 30, 2012. Financial Highlights for the quarter include: o Total revenue increased by 15% to $711,737 compared to $617,026 in the year-ago third quarter; o Gross profit improved to $484,205, a 23% increase over the year-ago third quarter of $395,104; o Gross profit margin increased to 68% compared to 64% in the year-ago third quarter; o Operating expenses, excluding non-recurring and non-cash expenses totaling $206,800, increased to $682,976…

WednesdayNov 14, 2012 6:39 pm

Nanosphere, Inc. (NSPH) Receives FDA Clearance to Market the Verigene CYP2C19 Test

Nanosphere, a leading provider of advanced molecular diagnostics systems, announced that the U.S. Food and Drug Administration has granted 510(k) clearance, permitting the marketing of the company’s CYP2C19 Nucleic Acid Test on the automated sample-to-result Verigene System. The Verigene CYP2C19 Test is indicated as an aid to help clinicians determine therapeutic strategy for drugs metabolized by the CYP450 2C19 genetic pathway. In less than 2.5 hours, the Verigene CYP2C19 Test identifies the CYP2C19 *2, *3, and *17 variations, if present, directly from a patient’s whole blood sample. The test gives physicians the crucial information they need to treat patients quickly…

WednesdayNov 14, 2012 6:38 pm

Jonathan B. Rome Named COO of Boston Therapeutics, Inc. (BTHE)

Yesterday, Boston Therapeutics announced that Mr. Jonathan B. Rome has been named as its Chief Operating Officer. David Platt, Ph.D., Boston’s CEO, remarked, “Jonathan Rome has more than 30 years’ experience and success in the sales, marketing and distribution of pharmaceutical products and developing collaborations around the world. Jonathan is an excellent choice to commercialize SUGARDOWN® and to lead the filing of an ANDA to market BTI-7.” Mr. Rome was the Founder, President, and CEO of ThePharmaNetwork, LLC, which was focused on pharmaceutical portfolio development, licensing, sales, marketing, and distribution of pharmaceuticals and APIs as well as sales, marketing, and…

WednesdayNov 14, 2012 6:38 pm

Quaterra Resources, Inc. (QMM) Shows Solid Intervals Like 2.62 feet at 54.5 Ounces Per Ton Silver in Newly Discovered Zone at Nieves Project

Quaterra Resources today reported excellent evidence of their model for the Nieves silver property in northern Zacatecas, Mexico, as assay results on eight core holes drilled (just over 10k feet total) from August through October come in via the company and its 50% JV partner, Blackberry Ventures I, LLC, offering positive correlation that there is indeed a sizeable, high-level hydrothermal system, potentially stretching well out beyond extant discoveries. Project Manager at the Nieves, Hector Fernandez, noted the long running analytical modality at QMM which projected the vein system’s extents considerably further to the west and how the intersection of 2.62…

WednesdayNov 14, 2012 6:37 pm

Consorteum Holdings, Inc. (CSRH) Files Form 10-K Report with SEC

Consorteum Holdings just announced that it filed its Report on Form 10-K for the fiscal year ended June 30, 2012, with the Securities and Exchange Commission and resumed its status as an issuer quoted on the OTCQB. The company also told investors that some of its affiliates, as well as Consorteum, entered into a settlement agreement with its former CEO and Chairman of its Board of Directors. The settlement agreement was filed as an exhibit to the Form 10-K Report. Subsequent to the execution of this agreement, Consorteum and its former CEO executed and delivered to each other general releases.…

WednesdayNov 14, 2012 6:35 pm

Cardium Therapeutics, Inc. (CXM) Presents Q3 Results, Plus Update on Business Activity

Cardium Therapeutics, a health sciences and regenerative medicine company, today presented financial results for the third quarter, ended September 30, 2012. The company also reported on recent developments, including the acquisition of To Go Brands nutraceutical brand platform, and various developments with Cardium’s Excellagen collagen-based topical gel for the treatment of wounds. Cardium reported a net loss of $1.9 million for the three months ended September 30, 2012, compared to a net loss of $1.6 million for the three months ended September 30, 2011. The increase in loss was due primarily to an increase in costs, resulting from expenses related…

WednesdayNov 14, 2012 6:35 pm

DoMark International, Inc. (DOMK) Rescues the Good Idea

It’s an unfortunate fact of business life that good ideas, even great ideas, are a dime a dozen. There isn’t a person alive that hasn’t had an idea pop into their head for a new product, a new service, a new technology, or just a new way of doing things. Ideas come from the recognition of a market need, even if the market itself doesn’t yet recognize it, and everyone occasionally becomes aware of a need. Of course, out of the thousands, even millions of good ideas out there, only a relative handful ever spark a working business, a startup…

TuesdayNov 13, 2012 6:51 pm

Cardium Therapeutics, Inc. (CXM) to Present Excellagen Posters at Desert Foot 9th Annual High Risk Diabetic Foot Conference

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, announced this morning that the company will be displaying two Excellagen® poster presentations at the Desert Foot 2012 High Risk Diabetic Foot Conference being held this week in Phoenix, AZ. Arthur J. Tallis, DPM, President and Medical Director of Associated Foot & Ankle Specialists in Phoenix, AZ, has been chosen to present the results of three Excellagen case studies, including a venous leg ulcer, neuropathic diabetic foot ulcer, and dehisced surgical wound. In addition, Howard M. Kimmel, DPM, MBA, FACFAS, Senior Clinical Instructor, Case Western Reserve University School of Medicine…

TuesdayNov 13, 2012 6:50 pm

VistaGen Therapeutics, Inc. (VSTA) Announces Enhancement of Predictive Liver Toxicology and Drug Metabolism Bioassay System

VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism screening, today announced a significant advance in its development of LiverSafe 3D™, a human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism issues in connection with the company’s drug rescue activities. Shawn K. Singh, VistaGen’s Chief Executive Officer, stated, “As we have done with CardioSafe 3D™, our stem cell-based bioassay system for predictive heart toxicity screening and drug rescue, we are developing LiverSafe 3D™ to change the game in drug development — to generate clinically predictive liver toxicology and…

TuesdayNov 13, 2012 6:49 pm

International Stem Cell Corp. (ISCO) Wholly Owned Subsidiary Launches New Stem Cell Based Skin Product in High Demand

International Stem Cell Corp., a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products, today announced Lifeline Skin Care’s commercial launch of its newest stem cell based skin care product. The new Lifeline® Eye Firming Complex is now available to shareholders, followers, and supporters of ISCO and Lifeline Skin Care. On Thursday the product will be available online (www.lifelineskincare.com), in selected spas, and medical clinics. “This addition to our skincare line has been highly anticipated,” says Donna Queen, President of Lifeline Skin Care. “An…

Site Search

Company Search

Month: November 2012